In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Zymeworks, with a price target of $32.00. The company’s ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Zymeworks, with a price target of $32.00. The company’s ...